Robert James Schultz

US Patent:

6616914, Sep 9, 2003

Filed:

Jul 17, 2001

Appl. No.:

09/907393

Inventors:

Gary Ward - San Diego CA
Robert Schultz - San Diego CA

Assignee:

Elan Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 912

US Classification:

424 45, 424 46, 424489, 424499, 514 2, 514 3, 514866, 12820014, 12820315

Abstract:

In a powder formulation for use in a dry powder inhaler, a pharmaceutical acts as its own carrier, so that use of lactose or other excipients are not needed. The dry powder formulation has a single active pharmaceutical compound having two major populations in particle size distribution: microfine particles of the active pharmaceutical, of 1-10 microns in diameter, and larger carrier particles, also of the active pharmaceutical compound. The carrier particles provide a long acting, delayed onset, and optionally therapeutic effect via the GI tract, while the microfine particles provide a fast onset effect via the lung.

US Patent:

7101534, Sep 5, 2006

Filed:

May 31, 1995

Appl. No.:

08/455874

Inventors:

Robert K. Schultz - San Diego CA, US
David W. Schultz - St. Paul MN, US
Robert A. Moris - Lino Lakes MN, US

Assignee:

3M Innovative Properties Company - St. Paul MN

International Classification:

A61K 9/00
A01N 25/02
A61L 9/04

US Classification:

424 43, 424 45

Abstract:

Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

US Patent:

7105152, Sep 12, 2006

Filed:

May 31, 1995

Appl. No.:

08/455490

Inventors:

Robert K. Schultz - San Diego CA, US
David W. Schultz - St. Paul MN, US
Robert A. Moris - Lino Lakes MN, US

Assignee:

3M Innovative Properties Company - St. Paul MN

International Classification:

A61K 9/00
A01N 25/02
A61L 9/04

US Classification:

424 43, 424 45

Abstract:

Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

US Patent:

8236340, Aug 7, 2012

Filed:

Jun 10, 2008

Appl. No.:

12/136576

Inventors:

Robert K Schultz - Poway CA, US

Assignee:

REVA Medical, Inc. - San Diego CA

International Classification:

A61F 2/02

US Classification:

424423

Abstract:

The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.

US Patent:

20040224003, Nov 11, 2004

Filed:

Feb 6, 2004

Appl. No.:

10/773756

Inventors:

Robert Schultz - Poway CA, US

International Classification:

A61K031/739
A61K031/355

US Classification:

424/423000, 514/579000, 514/054000, 514/458000

Abstract:

The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.

US Patent:

20110213456, Sep 1, 2011

Filed:

May 5, 2011

Appl. No.:

13/101391

Inventors:

Donald K. Brandom - La Mesa CA, US
James E. McGrath - Blacksburg VA, US
Joan Zeltinger - Encinitas CA, US
Eric V. Schmid - San Diego CA, US
Robert K. Schultz - Poway CA, US

Assignee:

REVA Medical, Inc. - San Diego CA

International Classification:

A61F 2/82
C08F 220/18
C08F 8/14

US Classification:

623 115, 526293, 525386

Abstract:

Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.

US Patent:

56450516, Jul 8, 1997

Filed:

Apr 21, 1995

Appl. No.:

8/426600

Inventors:

Robert K. Schultz - Poway CA
Robert F. Eisele - Laguna Niguel CA

Assignee:

Dura Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61M 1500

US Classification:

12820315

Abstract:

A dry powder inhaler has a front section holding a unit dose cartridge over a mixing chamber. An impeller is rotatably mounted within the mixing chamber. A rear section of the inhaler includes a motor, a breath actuated switch, and pins for positioning the unit dose cartridge in the front section and driving a plunger through the unit dose cartridge, to deposit a powdered drug into the mixing chamber, as the front and rear sections are brought together. A filter wheel allows air to flow forward from the rear section into the mixing chamber, but substantially prevents stray drug powder from migrating rearwardly to the rear section. The front section is preferably disposable, while the rear section is advantageously reusable.

US Patent:

6116237, Sep 12, 2000

Filed:

Apr 24, 1997

Appl. No.:

8/847287

Inventors:

Robert Schultz - San Diego CA
Clyde Witham - San Diego CA
Malcolm Hill - San Diego CA

Assignee:

Dura Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61M 1500

US Classification:

12820315

Abstract:

A method for inhalation of a dry powder drug includes the steps of providing a dry powder drug composition having a drug particle size of from about 1-7 microns and a mass median aerodynamic diameter of the delivered aerosol of from about 3. 5 to 5. 5 microns. This composition is loaded into an inhaler which is generally flow rate independent, and with the inhaler having an inspiration flow resistance of about 0. 12 to 0. 21 (cmH. sub. 2 O). sup. 1/2 over the range of about 15-60 L/min. The patient inhales the drug composition from the inhaler with an inspiration flow rate of about 15-60 L/min, resulting in a delivery efficiency measured by respirable fraction greater than 20%.